Skyrizi effectiveness skin psoriasis biologic-experienced psoriatic arthritis patients?

Here’s a concise overview of how Skyrizi (risankizumab) performs in biologic‑experienced patients with plaque psoriasis or psoriatic arthritis (PsA).

Key points
- Skyrizi is an IL-23p19 inhibitor. It’s approved for moderate-to-severe plaque psoriasis and for PsA, and has shown meaningful efficacy in patients who have previously used biologics (e.g., TNF inhibitors or IL‑17 inhibitors).
- Dosing (for both conditions): 150 mg by subcutaneous injection at Weeks 0 and 4, then every 12 weeks.

Plaque psoriasis in biologic-experienced patients
- Efficacy: In pivotal psoriasis trials, risankizumab produced robust skin clearance (PASI responses) that were durable over time. In biologic-experienced subgroups, a substantial portion achieved PASI75 by Week 16 and many maintained responses through later time points.
- Practical takeaway: Even after prior biologic failure, many patients reach clear or near-clear skin with Skyrizi, and responses tend to be sustained with continued dosing.

Psoriatic arthritis in biologic-experienced patients
- Efficacy: In the PsA program (KEEPsAKE-1 and KEEP-SAKE-2), risankizumab significantly improved joint outcomes (ACR20/50/70) and other measures such as enthesitis and dactylitis. Benefits were seen in patients with prior TNF inhibitor exposure as well as in those without.
- Practical takeaway: Skyrizi can improve both skin and joint symptoms in PsA patients who have previously used biologics.

Safety snapshot (typical profile)
- Common adverse events: nasopharyngitis, upper respiratory infections, headaches, and fatigue.
- Immunogenicity: Anti-drug antibodies are uncommon with risankizumab and don’t usually ablate efficacy.
- Overall: Safety profile is generally consistent with prior studies in biologic-experienced populations.

Want specifics?
- If you’d like, I can pull exact efficacy numbers (e.g., PASI75/90 rates at Week 16 or Week 52, ACR20/50/70 rates) for biologic-experienced subgroups and separate by prior biologic type (TNF inhibitors vs IL‑17 inhibitors). I can also summarize any particular trial (e.g., UltIMMa-1/2 for psoriasis or KEEPsAKE-1/2 for PsA) with the exact figures.
- If you’re considering Skyrizi for yourself or someone else, tell me which condition (plaque psoriasis or PsA), what prior biologics were used, and any other medical details, and I’ll tailor the info and discuss dosing/timing and what to discuss with a clinician.